Dendritic cell (DC) vaccines induce specific immune responses that can selectively
eliminate target cells. In recent years, many studies have been conducted to explore DC …

Lymphocytes have always been among the prime targets in gene therapy, even more so
since chimeric antigen receptor (CAR) T cells have reached the clinic. However, other gene …

Lentiviral vectors have undergone several generations of design improvement to enhance
their biosafety and expression characteristics, and have been approved for use in human …

Human immunodeficiency virus type I (HIV) is the etiologic agent of acquired
immunodeficiency syndrome or AIDS. Vectors based upon HIV have been in use for over a …

Dendritic cells (DCs) are potent antigen-presenting cells that constitute a major component
of the immune system's role in the recognition, elimination, and tolerance of cancer. The …

Background A number of gene therapy applications would benefit from vectors capable of
expressing multiple genes. In this study we explored the feasibility and efficiency of …

Despite the extensive research efforts over the past 25 years that have focused on HIV, there
is still no cure for AIDS. However, tremendous progress in the understanding of the structure …

Nowadays, cancers still represent a significant health burden, accounting for around 10
million deaths per year, due to ageing populations and inefficient treatments for some …

Immunotherapy is playing an increasing role in the treatment of many cancers. The recent
advances in antibody therapy gives much optimism that both passive (antibody therapy) as …

Lentiviral-mediated gene delivery holds significant promise for sustained gene expression
within living systems. Vesicular stomatitis virus glycoprotein-pseudotyped human …